Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome
Juan María Roldán‐Romero(European Bioinformatics Institute), Cristina Rodríguez‐Antona(Instituto de Salud Carlos III), Luis J. Leandro‐García(Spanish National Cancer Research Centre), Jesús García-Donás(Universidad San Pablo CEU), Javier Lanillos(Spanish National Cancer Research Centre), Pablo Maroto(Hospital de Sant Pau), Bruna Calsina(Spanish National Cancer Research Centre), María Monteagudo(Spanish National Cancer Research Centre), Mercedes Robledo(The University of Texas at San Antonio Health Science Center), María Santos(Spanish National Cancer Research Centre), Geòrgia Anguera(Hospital de Sant Pau), Cristina Montero‐Conde(Spanish National Cancer Research Centre), Alberto Cascón(Spanish National Cancer Research Centre), Guillermo de Velasco(Hospital Universitario 12 De Octubre), Rocío Letón, Ángel M. Martínez‐Montes(Spanish National Cancer Research Centre), Eduardo Caleiras(Spanish National Cancer Research Centre)
Cited by 56
Related Papers
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
|European Journal of Cancer|2012|588
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma
|Nature Genetics|2011|528
Dose-Response Association of CD8<sup>+</sup> Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
|JAMA Oncology|2017|409
Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension
|Journal of Hypertension|2020|406
Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas
|Human Molecular Genetics|2013|394